Octreotide - A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Conditions Associated with Excessive Peptide Secretion

Drugs

Volumn 38, Issue 5, 1989, Pages 658-702

  Battershill, Paul E ^a   Clissold, Stephen P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; OCTREOTIDE; SOMATOSTATIN;

ACROMEGALY; ANIMAL EXPERIMENT; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL ARTICLE; CRYPTOSPORIDIOSIS; DIARRHEA; DRUG ABSORPTION; DRUG METABOLISM; FISTULA; GASTRINOMA; GLUCAGONOMA; HUMAN; HUMAN EXPERIMENT; INSULINOMA; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VIPOMA;

ANIMAL; HUMAN; OCTREOTIDE; PEPTIDES;

EID: 0024317498     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198938050-00002     Document Type: Article

References (217)

1. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers
2. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome
3. Treatment of pancreatic fistula with the somatostatin analogue SMS 201–995
4. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide)
5. Influence of a long-acting somatostatin analogue (SMS 201–995) in acromegalic patients
6. Use of a somatostatin analog (SMS 201–995) in the glucagonoma syndrome
7. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201–995
8. Evaluation of a long acting somatostatin analogue (SMS 201–995) in patients with acromegaly
9. Effect of SMS 201–995 administration in 8 patients with active acromegaly
10. Treatment of acromegaly with the long-acting somatostatin analog SMS 201–995
11. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201–995)
12. Effective control of variceal bleeding by somatostatin: a double-blind, randomized, crossover study. Abstract
13. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action
14. SMS 201–995 and variceal haemorrhage
15. Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201–995
16. Control of watery diarrhoea syndrome in a patient with a vasoactive intestinal peptide-secreting tumour, using SMS 201–995 and dexamethasone
17. Severe upper gastrointestinal bleeding; guidelines for treatment
18. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201–995
19. Ineffectiveness of SMS 201–995 in severe hyperinsulinemia
20. Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin
21. Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201–995)
22. Pancreatic islet cell tumors
23. Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201–995 in a newborn with nesidioblastosis
24. Neuroendocrine tumors: a European view
25. Evaluation of SMS 201–995 in gastrointestinal APUDomas
26. Rebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201–995) in malignant gastrinoma
27. Improvement of psoriasis with chronic use of somatostatin (SMS) analogue SMS 201–995. Abstract
28. Effect of somatostatin analogue (SMS 201–995) on molecular species of gastrin in gastrinoma
29. Protracted administration of somatostatin to patients with pancreatic fistulas: clinical and endocrine evaluation
30. Medical treatment of acromegaly with SMS 201–995, a somatostatin analog: a comparison with bromocriptine
31. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue
32. Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production
33. Long term treatment of acromegaly with a long acting analogue of somatostatin
34. The role of somatostatin and a long-acting analogue, SMS 201–995, in acute bleeding due to peptic ulceration
35. Regression of metastatic vipoma with somatostatin analogue SMS 201–995
36. SMS 201–995 and endocrine tumours
37. Pharmacology and use in pituitary tumors. In Gordon P (Moderator) Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
38. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue
39. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201–995 in acromegaly
40. Insulinoma
41. Somatostatin treatment for cryptosporidial diarrhea in a patient with the Acquired Immunodeficiency Syndrome (AIDS)
42. Somatostatin and ranitidine in the control of iatrogenic haemorrhage of the upper gastrointestinal tract
43. Endocrine tumours of the pancreas
44. The anterior pituitary
45. Effects of somatostatin analogue SMS 201–995 in normal man
46. Closure of a high-output external pancreatic fistula by SMS 201–995, a long-acting analogue of somatostatin
47. Long-term treatment of an infant with nesidioblastosis using a somatostatin analogue
48. Endocrine profile of a long-acting somatostatin derivative SMS 201–995: study in normal volunteers following subcutaneous administration
49. Somatostatin: an evaluation of its utility as adjunctive medication for ERCP
50. Somatostatin in persistent gastrointestinal fistula treated by total parenteral nutrition. Correspondence
51. Treatment of acromegaly with the somatostatin analogue SMS 201–995
52. A comparison of the effect of levo-dopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly
53. Editorial. Bleeding oesophageal varices. Lancet 1: 139–141, 1984
54. Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea
55. The effect of somatostatin analogue SMS 201–995 on fluid and electrolyte transport in a patient with secretory diarrhoea
56. Effect of somatostatin on basal and glucose-induced insulin release in five patients with hyperinsulinaemia
57. Modulation of functional gastrointestinal endocrine tumors by endogenous and exogenous somatostatin
58. Observations on the effect of a somatostatin analog in the Zollinger-Ellison Syndrome: implications for the treatment of apudomas
59. Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison Syndrome by long-acting somatostatin (SMS 201–995)
60. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201–995
61. Inappropriate secretion of thyrotropin by the pituitary
62. Fasting hypoglycemia in adults
63. Short-term effects of the long-acting somatostatin analogue SMS 201–995 in five cases of APUDoma (four with metastases) and in one case of systemic mastocytosis
64. Effets de la Sandostatine administrée en injections répétées é doses croissantes, dans le traitement de 40 acromégales
65. The effect of a long-acting somatostatin analogue (SMS201-995) on intermediary metabolism and gut hormones after a test meal in normal subjects
66. Effect of a long-acting somatostatin analogue (SMS 201–995) on postprandial gastric emptying of 99mTc-Tin Colloid and mouth-to-caecum transit time in man
67. Oral absorption of the somatostatin analogue SMS 201–995: theoretical and practical implications
68. Small bowel fistulas treated with somatostatin: preliminary results
69. The somatostatin analogue SMS 201–995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones
70. Effect of SMS 201–995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma
71. Visual improvement with SMS 201–995 in a patient with a thyrotropin-secreting pituitary adenoma
72. Action of growth-hormone-release inhibitory hormone in healthy men and acromegaly
73. The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly
74. The use of SMS 201–995 (Somatostatin analogue) in insulinomas
75. Lung carcinoid with Cushing’s syndrome: control of serum ACTH and cortisol levels using SMS 201–995 (sandostatin)
76. A comparison of the effects of two somatostatin analogues in a patient with an external pancreatic fistula
77. Conservative treatment of fistulas of the pancreas and small intestine with somatostatin
78. Thyrotropin-producing pituitary adenomas
79. Short-term management of nesidioblastosis using the somatostatin analogue SMS 201–995
80. Treatment of postprandial hypotension with a somatostatin analogue (SMS 201–995)
81. Glucagon-producing tumors
82. Treatment of the dumping syndrome with the somatostatin analogue SMS 201–995
83. Treatment of the dumping syndrome with the somatostatin analogue SMS 201–995
84. Effect of a single administration of somatostatin analogue (SMS 201–995) on GH, TSH and insulin secretion in patients with acromegaly
85. Treatment of acromegaly with long acting somatostatin analogue SMS 201–995
86. Long-acting somatostatin analog in refractory neonatal hypoglycemia: follow-up information. Correspondence
87. Long-term treatment of refractory neonatal hypoglycemia with long-acting somatostatin analog
88. Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201–995
89. A prospective randomised controlled clinical trial comparing somatostatin and vaso Zin in controlling acute variceal haemorrhage
90. Efficacy of somatostatin and vasopressin in the control of acute variceal hemorrhage
91. Effects of a somatostatin analogue SMS 201–995 on hepatic haemodynamics in the pig and on intravariceal pressure in man
92. Gastrinoma
93. Effects of SMS 201–995 on intermediary metabolism and endocrine status in normal and diabetic humans
94. Effects of somatostatin and SMS 201–995 on carbohydrate metabolism in normal man
95. Somatostatin analogue SMS 201–995 long term therapy for vipoma
96. Effect of the long-acting somatostatin analogue SMS 201–995 on the glycaemic control in insulin-treated diabetics
97. Treatment of severe cryptosporidium-related diarrhea with octreotide in a patient with AIDS
98. Somatostatin and cimetidine in peptic ulcer haemorrhage
99. Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma
100. Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage
101. Long-term treatment of a vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
102. Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects
103. Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage
104. Gastrointestinal endocrine tumors: diagnosis and management. Role of somatostatin analogue SMS 201–995
105. Pharmacokinetics of SMS 201–995 in healthy subjects
106. Metastatic carcinoid tumors and the carcinoid syndrome
107. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995)
108. Rapid reversal of carcinoid crisis with a somatostatin analogue
109. Treatment of the malignant Carcinoid Syndrome: evaluation of a long-acting somatostatin analogue
110. Non-pituitary actions of somatostatin: a review on the therapeutic role of SMS 201–995 (Sandostatin)
111. A guide to the clinical use of the somatostatin analogue SMS 201–995 (Sandostatin)
112. Acute and long-term effects of SMS 201–995 in acromegaly
113. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995
114. Somatostatin analog treatment of acromegaly: new aspects
115. The somatostatin analog SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients
116. SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years
117. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995
118. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201–995 in patients with prolactinomas and acromegaly
119. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201–995, bromocriptine, and the combination of both drugs
120. Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract
121. Upper gastrointestinal bleeding: the trials of trials
122. Effect of the somatostatin analogue somatostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal man
123. The role of a long-acting somatostatin analogue (SMS 201–995) in the management of a patient with a benign insulin-secreting adenoma of the pancreas and a postoperative pancreatic fistula
124. The effect of SMS 201–995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers
125. Suppression of pancreatic endocrine tumor secretion by long-acting somatostatin analogue
126. Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas)
127. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide
128. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia
129. Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage
130. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue
131. Use in patients with gut neuroendocrine tumors. In Gorden P (Moderator) Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
132. Role of hepatic artery embolisation in the carcinoid syndrome
133. Effect of a long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera
134. Successful therapy of pancreatic cholera with the long-acting somatostatin analogue SMS 201–995: relation between plasma concentrations of drug and clinical and biochemical responses
135. Diagnosis and treatment of Zollinger-Ellison syndrome
136. An Odyssey in the land of small tumors
137. Streptozocin alone compared with Areptozocin plus fluorouracil in the treatment of islet-cell carcinoma
138. The use of somatostatin and its analog in the treatment of surgical disorders
139. Effect of a long-acting somatostatin derivative SMS 201–995 (Sandostatin) on glucose homeostasis in type I diabetes mellitus
140. Successful treatment of a VIPoma by continuous subcutaneous infusion of somatostatin analogue (SMS 201–995)
141. Effects of the somatostatin analogue SMS 201–995 on carcinoid flush
142. Blind evaluation of the effect of octreotide (SMS 201–995), a somatostatin analogue, on small-bowel fistula output
143. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results
144. Treatment of the carcinoid syndrome with SMS 201–995, a somatostatin analogue
145. Gut endocrinology: clinical and therapeutic impact
146. Endocrine tumors of the gastroenteropancreatic (GEP) axis
147. Use of a long-acting somatostatin analogue (SMS 201–995) in controlling a significant ileal output in a 5-year-old child
148. Homogeneity in the growth hormone-lowering effect of dopamine and somatostatin in acromegaly
149. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation
150. Malignant insulinoma: effects of a somatostatin analog (compound 201–995) on serum glucose, growth, and gastro-entero-pancreatic hormones
151. Chronic effects of somatostatin (SMS) analog (201–995) may be independent of suppression of endogenous insulin secretion. Abstract
152. The use of a long acting somatostatin analogue (SMS 201–995) in pancreatic fistulae: a preliminary report
153. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin
154. Heterogeneous forms of thyroid-stimulating hormone in mouse thyrotropic tumor and serum: differences in receptor-binding and adenylate cyclase-stimulating activity
155. Somatostatin sensitivity and growth hormone responses to releasing hormones and bromocriptine in acromegaly
156. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995
157. Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin
158. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly
159. Somatostatin analogue SMS 201–995 in type I diabetes mellitus: initial experience after repeated administration
160. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995 over 6 months
161. Treatment of pancreatic cutaneous fistulas with a somatostatin analog
162. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors
163. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses
164. High density of somatostatin receptors in pituitary tumors from acromegalic patients
165. Short-term administration of the somatostatin analogue SMS 201–995 in patients with carcinoid tumours
166. SMS 201–995, a somatostatin analogue, and diarrhea in the acquired immunodeficiency syndrome (AIDS)
167. Administration of somatostatin analog (SMS 201–995) in the treatment of a fistula occurring after pancreas transplantation: interference with cyclosporine immunosuppression
168. Octreotide: a synthetic analog of somatostatin
169. Long-acting somatostatin (SMS 201–995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy
170. Demonstration of tumor regression with somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera
171. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201–995)
172. Pseudopancreatic cholera syndrome: effect of a synthetic somatostatin analogue, SMS 201–995
173. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport
174. VIPoma syndrome: effect of a synthetic somatostatin analogue
175. Treatment of APUDomas with the long-acting somatostatin analogue SMS 201–995
176. Somatostatin analog SMS 201–995 and insulin needs in insulin-dependent diabetic patients studied by means of a artificial pancreas
177. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201–995
178. Somatostatin in treatment of haematemesis and malaena
179. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome
180. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations
181. Effect of short- and long-term treatment with SMS 201–995 in patients with carcinoid tumours
182. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201–995
183. Bromocriptine therapy for hyperthyroidism due to increased thyrotropin secretion
184. Long-term management of acromegaly with sandostatin
185. Therapeutic efficacy of a somatostatin analogue (SMS 201–995) in active acromegaly
186. Perioperative use of long-acting somatostatin analog (SMS 201–995) in patients with endocrine tumors of the gastroenteropancreatic axis
187. SMS 201–995: studies in acromegaly and in normal men
188. SMS 201–995 treatment of acromegaly: reduction in tumour size and growth hormone secretion. Abstract
189. Glucose tolerance during long term treatment with a somatostatin analogue
190. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma
191. Somatostatin analogue (SMS 201–995) in patients with gastrinomas
192. Somatostatin analogue (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes
193. Treatment of metastasizing GRF-producing tumour with a long-acting somatostatin analogue. Correspondence
194. Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201–995) in a girl with gigantism
195. Somatostatin octapeptide (SMS 201–995) in the medical treatment of acromegaly
196. Long term treatment with the somatostatin analog SMS 201–995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma
197. Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue
198. Tumor regression of an ileal carcinoid under treatment with the somatostatin analogue SMS 201–995
199. Clinical evaluation of SMS 201–995: long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion
200. Postprandial effects of SMS 201–995 on gut hormones and glucose tolerance
201. Hyperthyroidism due to non-tumoural inappropriate TSH secretion: effect of a long-acting somatostatin analogue (SMS 201–995)
202. Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea
203. Long-term use of somatostatin analogue SMS 201–995 in the treatment of hypoglycaemia due to nesidioblastosis
204. Reduction of pituitary size by the somatostatin analogue SMS 201–995 in a patient with an islet cell tumour secreting growth hormone releasing factor
205. Principles of endocrinology
206. Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery
207. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses
208. Treatment of relapsing bleeding peptic ulcers with the somatostatin analogue SMS 201–995 in a patient with Zollinger-Ellison syndrome